Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: pyrotinib.
- Кому может быть актуально
- Состояния в реестре: Locally Advanced Breast Cancer. Базовые параметры: 18 лет — 70 лет · Женщины.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Китай
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Adjuvant Trastuzumab Plus Pyrotinib for Residual Invasive HER2-positive Breast Cancer After Neoadjuvant Chemotherapy Plus Anti-HER2 Target Therapy
Обзор
This is a prospective, randomised, multicenter, no placebo-controlled, open label study for evaluating the efficacy and safety of pyrotinib in women with residual invasive HER2-positive breast cancer after neoadjuvant chemotherapy plus anti-HER2 target therapy. The main purpose is to investigate whether pyrotinib can further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer based on the 1-year trastuzumab standard adjuvant treatment with or without pertuzumab.
Вмешательства
- Препарат pyrotinib
pyrotinib 400 mg, orally once daily for one year
Первичные конечные точки
- Invasive Disease-free Survival (iDFS) [Срок оценки: From randomization until time of event up to 2 years.]
Вторичные конечные точки (2)
- Disease-free Survival (DFS) [Срок оценки: From randomization until time of event up to 2 years]
- Overall Survival (OS) [Срок оценки: From randomization until time of event up to 2 years]
Критерии участия
Критерии включения
- Female, Aged ≥18 and ≤70 years;
- Histologically confirmed invasive HER2 positive breast cancer, early disease(Stage ⅡA-Ⅲ) ;
- Completed neoadjuvant therapy, including chemotherapy and trastuzumab;
- Residual invasive disease was detected pathologically in the surgical specimen of the breast or axillary lymph nodes after completion of neoadjuvant chemotherapy;
- Been or being treated for early breast cancer with standard of care duration of trastuzumab;
- Adjuvant treatment regimen needs to be determined before randomization;
- Duration from Random time to the last use of trastuzumab≤1 year.
- Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1;
- Required laboratory values including following parameters:ANC: ≥ 1.5 x 109/L; Platelet count: ≥ 100 x 109/L; Hemoglobin: ≥ 9.0 g/dL; Total bilirubin: ≤ 1.5 x upper limit of normal, ULN; ALT and AST: ≤ 1.5 x ULN; BUN and creatine clearance rate: ≥ 50 mL/min; LVEF: ≥ 50%; QTcF: < 470 ms
- Signed informed consent form (ICF) .
Критерии исключения
- Metastatic disease (Stage IV) ;
- Gross residual disease remaining after mastectomy or positive margins after breast-conserving surgery;
- Progressive disease during neoadjuvant therapy;
- Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption;
- Treated or treating with anti-HER2 TKI, including but not limited to pyrotinib, lapatinib and neratinib.
- Less than 4 weeks from the last clinical trial;
- History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation;
- Subjects had any heart disease, including: (1) angina; (2) requiring medication or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) Any heart diseases judged by investigator as unsuitable to participate in the trial;
- Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period;
- Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Распределение
- Рандомизированное
- Модель
- Параллельные группы
- Маскирование
- Открытое
- Основная цель
- Лечение
Центры проведения
Китай · 1 центр
- Renji Hospital, School of Medicine, Shanghai Jiao Tong University — Шанхай
Идентификаторы
NCT: NCT04254263 · KY2019-070